8 Dec 2009 07:00
For Immediate Release 8 December 2009
ALLIANCE PHARMA PLC
("Alliance" or "the Company")
Exercise of Options
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of options on 7 December 2009, application has been made by Alliance for a further 57,625 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading AIM.
It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 11 December 2009.
Following the exercise of these options, Alliance will have 193,319,398 Ordinary Shares in issue.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive | |
| Richard Wright, Finance Director | |
| www.alliancepharma.co.uk | |
| Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Stasa Filiplic / Jennie Spivey | |
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs | |
| Corporate Broking: David Poutney / James Serjeant |
Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 37 branded pharmaceutical products and continues to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)